162 related articles for article (PubMed ID: 18385254)
1. Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop.
Duenas-Decamp MJ; Peters P; Burton D; Clapham PR
J Virol; 2008 Jun; 82(12):5807-14. PubMed ID: 18385254
[TBL] [Abstract][Full Text] [Related]
2. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.
Pantophlet R; Ollmann Saphire E; Poignard P; Parren PW; Wilson IA; Burton DR
J Virol; 2003 Jan; 77(1):642-58. PubMed ID: 12477867
[TBL] [Abstract][Full Text] [Related]
3. The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodies.
Dueñas-Decamp MJ; O'Connell OJ; Corti D; Zolla-Pazner S; Clapham PR
Retrovirology; 2012 Jan; 9():9. PubMed ID: 22284192
[TBL] [Abstract][Full Text] [Related]
4. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.
Koch M; Pancera M; Kwong PD; Kolchinsky P; Grundner C; Wang L; Hendrickson WA; Sodroski J; Wyatt R
Virology; 2003 Sep; 313(2):387-400. PubMed ID: 12954207
[TBL] [Abstract][Full Text] [Related]
5. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120.
Zwick MB; Parren PW; Saphire EO; Church S; Wang M; Scott JK; Dawson PE; Wilson IA; Burton DR
J Virol; 2003 May; 77(10):5863-76. PubMed ID: 12719580
[TBL] [Abstract][Full Text] [Related]
6. Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.
Wu L; Zhou T; Yang ZY; Svehla K; O'Dell S; Louder MK; Xu L; Mascola JR; Burton DR; Hoxie JA; Doms RW; Kwong PD; Nabel GJ
J Virol; 2009 May; 83(10):5077-86. PubMed ID: 19264769
[TBL] [Abstract][Full Text] [Related]
7. Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.
Utachee P; Isarangkura-na-ayuthaya P; Tokunaga K; Ikuta K; Takeda N; Kameoka M
Retrovirology; 2014 Apr; 11():32. PubMed ID: 24758333
[TBL] [Abstract][Full Text] [Related]
8. Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.
Utachee P; Nakamura S; Isarangkura-Na-Ayuthaya P; Tokunaga K; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
J Virol; 2010 May; 84(9):4311-20. PubMed ID: 20164234
[TBL] [Abstract][Full Text] [Related]
9. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
[TBL] [Abstract][Full Text] [Related]
10. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.
Wu X; Zhou T; O'Dell S; Wyatt RT; Kwong PD; Mascola JR
J Virol; 2009 Nov; 83(21):10892-907. PubMed ID: 19692465
[TBL] [Abstract][Full Text] [Related]
12. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
[TBL] [Abstract][Full Text] [Related]
13. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
[TBL] [Abstract][Full Text] [Related]
14. Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120.
Wilkinson RA; Piscitelli C; Teintze M; Cavacini LA; Posner MR; Lawrence CM
J Virol; 2005 Oct; 79(20):13060-9. PubMed ID: 16189008
[TBL] [Abstract][Full Text] [Related]
15. A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.
Gach JS; Quendler H; Tong T; Narayan KM; Du SX; Whalen RG; Binley JM; Forthal DN; Poignard P; Zwick MB
PLoS One; 2013; 8(8):e72054. PubMed ID: 23991039
[TBL] [Abstract][Full Text] [Related]
16. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
Wu X; Wang C; O'Dell S; Li Y; Keele BF; Yang Z; Imamichi H; Doria-Rose N; Hoxie JA; Connors M; Shaw GM; Wyatt RT; Mascola JR
J Virol; 2012 May; 86(10):5844-56. PubMed ID: 22419808
[TBL] [Abstract][Full Text] [Related]
17. Structural definition of a conserved neutralization epitope on HIV-1 gp120.
Zhou T; Xu L; Dey B; Hessell AJ; Van Ryk D; Xiang SH; Yang X; Zhang MY; Zwick MB; Arthos J; Burton DR; Dimitrov DS; Sodroski J; Wyatt R; Nabel GJ; Kwong PD
Nature; 2007 Feb; 445(7129):732-7. PubMed ID: 17301785
[TBL] [Abstract][Full Text] [Related]
18. Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.
Sterjovski J; Churchill MJ; Ellett A; Wesselingh SL; Ramsland PA; Gorry PR
Virology; 2012 Oct; 432(2):394-404. PubMed ID: 22818780
[TBL] [Abstract][Full Text] [Related]
19. A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection.
Musich T; Peters PJ; Duenas-Decamp MJ; Gonzalez-Perez MP; Robinson J; Zolla-Pazner S; Ball JK; Luzuriaga K; Clapham PR
J Virol; 2011 Mar; 85(5):2397-405. PubMed ID: 21159865
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12.
Duenas-Decamp MJ; Clapham PR
J Virol; 2010 Sep; 84(18):9608-12. PubMed ID: 20610714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
